Outcomes of Pars Plana Vitrectomy with Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy Without Retinal Detachment: A Seven-Year Retrospective Study
Veshesh Patel,Landon J Rohowetz,Parastou Pakravan,Meghana Kalavar,Nicolas A Yannuzzi,Jayanth Sridhar
DOI: https://doi.org/10.2147/OPTH.S400474
2023-02-01
Clinical Ophthalmology
Abstract:Veshesh Patel, Landon J Rohowetz, Parastou Pakravan, Meghana Kalavar, Nicolas A Yannuzzi, Jayanth Sridhar Department of Ophthalmology, Bascom Palmer Eye Institute University of Miami, Miami, FL, USA Correspondence: Jayanth Sridhar, Department of Ophthalmology, Bascom Palmer Eye Institute, 900 NW 17th St, Miami, FL, 33136, USA, Tel +1 305 326-6124, Email Objective: To review clinical outcomes of patients with proliferative diabetic retinopathy (PDR) and vitreous hemorrhage (VH) who underwent pars plana vitrectomy (PPV) with endolaser panretinal photocoagulation (PRP) without retinal detachment (RD) repair. Methods: Retrospective chart review of the rate of postoperative clinical findings and visual acuity in patients with PDR from May 2014 to August 2021. Results: Pars plana vitrectomy with endolaser PRP was performed in 81 eyes of 81 patients (mean age of 62.1 ± 10.5 years). At a median follow-up of 18 months, mean Snellen best-corrected visual acuity (BCVA) significantly improved from 20/774 preoperatively to 20/53 at last follow-up ( P < 0.001). Postoperative complications and clinical findings included VH (12.3%), diabetic macular edema (DME) (12.3%), ocular hypertension (8.6%), RD (4.9%), and need for additional PPV (6.2%). Eyes with PRP performed within 6 months before surgery had a lower frequency of developing postoperative VH (5.3%) compared to eyes that received PRP more than 6 months before surgery (27.3%, P = 0.04). Eyes that received preoperative anti-vascular endothelial growth factor (VEGF) treatment (2.0%) had a lower frequency of postoperative VH compared to eyes that did not receive anti-VEGF treatment (14.3%, P = 0.04). Eyes that received intraoperative sub-tenon triamcinolone acetonide developed postoperative DME (4.0%) less frequently than eyes that did not receive sub-tenon triamcinolone acetonide (26.7%, P = 0.04). Conclusion: In patients with PDR and VH, PPV with PRP yielded significant improvements in visual acuity and resulted in overall low rates of recurrent postoperative VH. Preoperative anti-VEGF and PRP laser treatment were associated with lower rates of postoperative VH. Furthermore, intraoperative use of sub-tenon triamcinolone acetonide was associated with a lower rate of postoperative DME. Pars plana vitrectomy with endolaser PRP in conjunction with the aforementioned pre- and intraoperative therapies is an effective treatment for patients with PDR and VH. Keywords: pars plana vitrectomy, panretinal photocoagulation, vitreous hemorrhage, vascular endothelial growth factor, sub-tenon triamcinolone acetonide Diabetic retinopathy is a leading cause of severe vision loss, and proliferative diabetic retinopathy (PDR) represents the most severe form of this disease. 1 Treatment options for PDR include panretinal photocoagulation (PRP), intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy, and pars plana vitrectomy (PPV). Indications for PPV in patients with PDR include non-clearing vitreous hemorrhage (VH), vitreomacular traction, tractional retinal detachment, and diabetic macular edema (DME). Pars plana vitrectomy is typically accompanied with intraoperative endolaser PRP treatment to ischemic peripheral retina. 2,3 Previous authors have reported outcomes of eyes with PDR undergoing clinic-based PRP or PPV. 4–12 However, the preoperative factors associated with better post-procedural anatomic and functional status remain unclear. The purpose of this study was to determine the relative safety and efficacy of PPV with PRP and to identify clinical and demographic factors associated with postoperative outcomes. The study was approved by the Institutional Review Board at the University of Miami and conformed to the requirements of the United States Health Insurance Portability and Privacy Act. The need for patient consent was waived by the Institutional Review Board due to the retrospective nature of the study. This retrospective, interventional case series included patients with PDR who underwent PPV with PRP from May 1, 2014, to August 31, 2021, with a minimum of 3 months of follow-up time. Patients with proliferative diabetic retinopathy were identified using ICD-10 codes. The current procedural terminology (CPT) code 67040 was used to identify patients who underwent PPV with endolaser PRP without RDs within the study time period. Exclusion criteria included patient age less than 18, pregnancy at time of surgery, less than 3 months of follow-up, history of prior PPV, presence of retinal detachment (RD), and neovascular glaucoma. The following pre-operative data was collected: gender, date of birth, eye (OD/OS), race/ethnicity, duration of diabetes prior to surgery, type of diabetes, Hemoglobin A1c (HbA1c), -Abstract Truncated-